Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of their patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-650-2466400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
diaDexus (OTCMKTS:DDXS) Frequently Asked Questions
What is diaDexus' stock symbol?
diaDexus trades on the OTCMKTS under the ticker symbol "DDXS."
How were diaDexus' earnings last quarter?
diaDexus, Inc. (OTCMKTS:DDXS) released its quarterly earnings data on Monday, October, 26th. The company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.35. View diaDexus' Earnings History.
Has diaDexus been receiving favorable news coverage?
Media stories about DDXS stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. diaDexus earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are diaDexus' key executives?
diaDexus' management team includes the folowing people:
- Lori F. Rafield Ph.D., Chairman of the Board, Chief Executive Officer (Age 60)
- Leone D. Patterson, Chief Financial Officer (Age 54)
- Emi Zychlinsky Ph.D., Executive Vice President, Chief Technology Officer (Age 59)
- Christopher P Lowe, Chief Accounting Officer (Age 47)
- Jonathan Ruais, Vice President of Marketing
- Kenneth C. Fang M.D., Chief Medical Officer (Age 53)
- R. Michael Richey, Chief Business Officer (Age 60)
- James R. Sulat, Director (Age 66)
- John T. Curnutte M.D. Ph.D., Independent Director (Age 65)
- Karen Drexler, Independent Director (Age 56)
How do I buy shares of diaDexus?
Shares of DDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is diaDexus' official website?
How can I contact diaDexus?
diaDexus' mailing address is 349 Oyster Point Blvd, SOUTH SAN FRANCISCO, CA 94080-1947, United States. The company can be reached via phone at +1-650-2466400.
MarketBeat Community Rating for diaDexus (OTCMKTS DDXS)
MarketBeat's community ratings are surveys of what our community members think about diaDexus and other stocks. Vote "Outperform" if you believe DDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
